GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Cyclically Adjusted Price-to-FCF

Corbus Pharmaceuticals Holdings (LTS:0SZI) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Corbus Pharmaceuticals Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Cyclically Adjusted Price-to-FCF Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corbus Pharmaceuticals Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF falls into.


;
;

Corbus Pharmaceuticals Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Corbus Pharmaceuticals Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Corbus Pharmaceuticals Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.346/134.9266*134.9266
=-1.346

Current CPI (Mar. 2025) = 134.9266.

Corbus Pharmaceuticals Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.006 100.684 0.008
201509 -2.147 100.392 -2.886
201512 -0.775 99.792 -1.048
201603 -2.057 100.470 -2.762
201606 -2.050 101.688 -2.720
201609 -2.139 101.861 -2.833
201612 -3.769 101.863 -4.992
201703 -4.318 102.862 -5.664
201706 -3.441 103.349 -4.492
201709 -3.809 104.136 -4.935
201712 -5.398 104.011 -7.002
201803 -1.527 105.290 -1.957
201806 -3.271 106.317 -4.151
201809 -4.695 106.507 -5.948
201812 -7.502 105.998 -9.549
201903 4.982 107.251 6.268
201906 -7.256 108.070 -9.059
201909 -8.483 108.329 -10.566
201912 -11.064 108.420 -13.769
202003 -12.155 108.902 -15.060
202006 -10.809 108.767 -13.409
202009 -10.007 109.815 -12.295
202012 -6.236 109.897 -7.656
202103 -5.624 111.754 -6.790
202106 -4.519 114.631 -5.319
202109 0.205 115.734 0.239
202112 -2.335 117.630 -2.678
202203 -2.549 121.301 -2.835
202206 -2.933 125.017 -3.165
202209 -1.737 125.227 -1.872
202212 -1.787 125.222 -1.925
202303 -3.614 127.348 -3.829
202306 -1.824 128.729 -1.912
202309 -1.622 129.860 -1.685
202312 -1.358 129.419 -1.416
202403 -0.959 131.776 -0.982
202406 -0.809 132.554 -0.823
202409 -1.160 133.029 -1.177
202412 -0.898 133.157 -0.910
202503 -1.346 134.927 -1.346

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corbus Pharmaceuticals Holdings  (LTS:0SZI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Corbus Pharmaceuticals Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Headlines

No Headlines